|
Related Companies
|
[]
|
||||||||
|
Related Funds
|
[]
|
||||||||
|
|
|||||||||
|
English
|
|||||||||
|
oda_MaterialEventDisclosureGeneralAbstract|
|
|
||||||||
|
oda_UpdateAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
|
oda_CorrectionAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
|
oda_DateOfThePreviousNotificationAboutTheSameSubject|
|
|
-
|
|||||||
|
oda_DelayedAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
|
oda_AnnouncementContentSection|
|
|
||||||||
|
oda_ExplanationSection|
|
|
||||||||
|
oda_ExplanationTextBlock|
|
Regarding the Moderna COVID-19 vaccine named "mRNA-1273 (Spikevax)", our Emergency Use Approval application, which we filed before the Republic of Turkey Ministry of Health, Turkish Medicines and Medical Devices Agency (TİTCK) on 23.05.2022, has been approved by the Agency's letter dated 17.01.2023. In addition, it has been notified by the Agency that the procedures of registration in Turkey and GMP ( Good Manufacturing Practices ) inspection of the foreign manufacturing facility of the subject vaccine will be considered with HIGH PRIORITY.
|
||||||||